Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations
- PMID: 2562914
- DOI: 10.1001/archpsyc.1989.01810010022003
Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations
Abstract
3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a selective serotonin (5-HT) neurotoxin in laboratory animals. To assess its effects on 5-HT function in humans, serum prolactin (PRL) and mood responses to intravenous L-tryptophan were measured in nine recreational users of MDMA and compared with findings from nine matched healthy controls. L-Tryptophan induced a rise in the PRL concentration in controls, but not in MDMA users. Peak change and the area under the curve of the PRL response appeared to be blunted in MDMA users, but the difference from controls did not reach statistical significance. This study provides suggestive evidence of altered 5-HT function in MDMA users, but more definitive studies clearly are needed.
Comment in
-
Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity.Arch Gen Psychiatry. 1990 Mar;47(3):288-9. doi: 10.1001/archpsyc.1990.01810150088014. Arch Gen Psychiatry. 1990. PMID: 1968330 Clinical Trial. No abstract available.
Similar articles
-
Responses to i.v. L-tryptophan in MDMA users.NIDA Res Monogr. 1989;95:421-2. NIDA Res Monogr. 1989. PMID: 2577044 No abstract available.
-
Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.Neuropsychopharmacology. 1994 Apr;10(2):129-38. doi: 10.1038/npp.1994.15. Neuropsychopharmacology. 1994. PMID: 7517677 Clinical Trial.
-
Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.Psychopharmacology (Berl). 1999 Nov;147(1):56-65. doi: 10.1007/s002130051142. Psychopharmacology (Berl). 1999. PMID: 10591869 Clinical Trial.
-
Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").J Neurochem. 1990 Jan;54(1):14-22. doi: 10.1111/j.1471-4159.1990.tb13277.x. J Neurochem. 1990. PMID: 1967141 Review. No abstract available.
-
(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.Neuropsychobiology. 2000;42(1):11-6. doi: 10.1159/000026665. Neuropsychobiology. 2000. PMID: 10867551 Review.
Cited by
-
Acute poisoning with amphetamines (MDEA) and heroin: antagonistic effects between the two drugs.Intensive Care Med. 1996 May;22(5):456-9. doi: 10.1007/BF01712166. Intensive Care Med. 1996. PMID: 8796401
-
Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.J Neural Transm (Vienna). 1997;104(8-9):771-94. doi: 10.1007/BF01285547. J Neural Transm (Vienna). 1997. PMID: 9451711 Review.
-
Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").Psychopharmacology (Berl). 1995 Jun;119(3):247-60. doi: 10.1007/BF02246288. Psychopharmacology (Berl). 1995. PMID: 7675958 Review.
-
Rat strain differences in the vulnerability of serotonergic nerve endings to neurotoxic damage by p-chloroamphetamine.J Neural Transm (Vienna). 1996;103(12):1381-95. doi: 10.1007/BF01271252. J Neural Transm (Vienna). 1996. PMID: 9029405
-
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.Drug Saf. 1996 Aug;15(2):116-34. doi: 10.2165/00002018-199615020-00004. Drug Saf. 1996. PMID: 8884163 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical